Marathon Patent Group Inc. (NASDAQ:MARA)’s Q3 Revenues Grows 280%

Marathon Patent Group Inc. (NASDAQ:MARA)

Marathon Patent Group Inc. (NASDAQ:MARA) traded higher after the company reported Q3 financial results that beat Wall Street expectations. Shares of the company gained 5.04% in Monday’s trading session to end the day at $1.46 a share.

Marathon Patent Group Inc. (NASDAQ:MARA)

MARA Stock Performance

The company generated revenues of $163 million for the three months ended September 30, 2017, up from revenues of $43,000 reported in Q3 2016. Operating loss for the period dropped to $3.9 million, compared to $10.7 million reported last year.

Despite the 5% rally, Marathon Patent Group Inc. (NASDAQ:MARA) is still trading in a downtrend. The IP licensing company has shed more than 70% in market value and is currently trading near its 52-week low of $0.50 a share.

Last month, the company was forced to initiate a reverse stock-split of its common stock in a bid to shore up its share price. The split was primarily intended to bring the company in compliance with the minimum average closing share price for continued listing in the NASDAQ Capital Market. A 4:1 reverse stock-split consequently reduced the company’s common stock from approximately 32.4 million shares to approximately 8.6 million shares.

Investor’s sentiments on the stock appear to have hit all-time lows despite the company making huge strides on revenue growth. It awaits to be seen if the stellar Q3 financial results is the catalyst that will help push the stock from current lows.

GBV Acquisition

In a bid to strengthen investor confidence in the stock, Marathon Patent Group Inc. (NASDAQ:MARA) announced the acquisition of Global Bit Ventures. The acquisition is part of the company’s plan to diversify its areas of operations. The company is currently eyeing growth opportunities in the digital currency space with the acquisition.

Global Bit Ventures joins Marathon Patent Group Inc. (NASDAQ:MARA) with a robust infrastructure around cryptocurrencies, with significant capability for expansion. The company boasts of a technology that powers and secures blockchains by operating custom hardware and software. It also owns 250GH/s of GPU mining servers.

“We previously expressed our intent to review alternative business directions with the goal of enhancing shareholder value. We believe the acquisition of Global Bit Ventures will take advantage of an ongoing revolution in digital transactions conducted on blockchains as we see increasing adoption and proliferation of blockchain protocols in our everyday lives,” said CEO, Doug Croxall.

According to GBV CEO, the merger marks an important milestone and sets the company on course for accelerated revenue growth

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MARA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) Jumps on Court Decision

Digital Ally, Inc. (NASDAQ:DGLY)

Shares of Digital Ally, Inc. (NASDAQ:DGLY) are up 18% after the company won a court ruling which should send the issue to trial. The market reacted favorably to the decision by the Federal District Court of Kansas after it rejected the request of Axon Enterprise, Inc. (Axon) to maintain the stay of the patent lawsuit brought against it by Digital Ally.

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Its products are distributed globally. The company’s products include in-car and body cameras, cloud and local management software, and automatic recording technology. The products have been designed to work seamlessly together.

On November 8, 2017, the company’s Board of Directors decided to explore strategic alternatives. Avenues may include monetizing its patent portfolio and related patent infringement litigation against Axon, the sale of Digital Ally as a whole, or the sale of select properties or groups of properties or individual businesses. The result of the strategic review may also include the continued implementation of the company’s business plan. The Company has retained Roth Capital Partners LLC to assist in this process.

Digital Ally Accused of Patent Infringement

The litigation between Digital Ally, Inc. (NASDAQ:DGLY) and Axon involves two patents — the ‘452 Patent and U.S. Patent No. 8,781,292 (“the ‘292 Patent”). The ‘452 Patent generally covers the automatic activation and coordination of multiple recording devices in response to a triggering event such as a law enforcement officer activating the light bar on the vehicle. Within the Axon product family, the “Signal” component is responsible for this functionality. The ‘292 Patent is asserted against Axon’s Signal Performance Power Magazine (SPPM) – a battery pack that incorporates Signal and is designed to activate one or more body cameras when the safety of a conducted electrical weapon is deactivated.

On July 6, 2017, the U.S. Patent Office denied Axon’s petition for inter partes review of Digital’s ‘452 Patent. On August 3, 2017, the Patent Office denied Axon’s final petition for IPR of the ‘452 Patent. This was Axon’s final attempt to invalidate the ‘452 Patent before the Patent Office.

Last Friday, November 17, 2017, the Court rejected Axon’s request and lifted the stay of the litigation. In ruling on the motion regarding the stay, the Court found that the evidence submitted by Digital Ally, Inc. (NASDAQ:DGLY) “weigh heavily against continuing the stay of the ‘452 patent” and that “the Court denies Defendant’s [Axon’s] request to continue the stay of this case with respect to the ‘452 patent.” The Court has set a hearing for December 14, 2017, to discuss a schedule for moving the case forward to trial.

DGLY Stock Performance

Digital Ally, Inc. (NASDAQ:DGLY) has a market capitalization of $16.1 million and a float of just 5.73 million shares. This makes it a frequent subject of day-trading chat rooms and frequent jumps in trading volume.

Year-to-date, DGLY stock has lost over 44% but is up 4.5% for the past week. It has a consensus, one-year target price of $6 – a price which was established early in 2017 and is also its 52-week high. Since then, the stock has largely slid downwards to $1.70, its 52-week low which was hit earlier this month.

Three investment firms cover Digital Ally, Inc. (NASDAQ:DGLY). Two rate DGLY stock as a “strong Buy”, while one rates the shares as a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DGLY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

OncoSec Medical Inc. (NASDAQ:ONCS

OncoSec Medical Inc. (NASDAQ:ONCS) Hits Record Highs after Trial Results

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) hit a new record high after the company reported positive follow-up data from its Phase 2 OMS 1-102 combination study of ImmunoPulse IL-12 and Keytruda. The stock was up by 60% in Monday’s trading session to end the day at $2 a share.

OncoSec Medical Inc. (NASDAQ:ONCS

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) is currently trading in an uptrend, after being in consolidation for the better part of the year. For the full year, the stock is up by more than 60%. Following the rally, Maxim analyst Jason Kolbert has assigned a ‘Buy’ rating on the stock with a share price target of $5. The price target represents a 146% potential upside from current trading levels.

Renewed investor interest on the stock follows the announcement that a combination of ImmunoPulse il-12 and Keytruda demonstrated a 57% progression-free survival at 15 months.

Trial Results

According to OncoSec Medical Inc. (NASDAQ:ONCS), the new data demonstrates that a combination of the two therapies can prime a coordinated innate and adaptive immune response. The findings also suggest that the approach can reshape the tumor microenvironment yielding a robust anti-tumor response.

“The robust PFS benefit and tolerability observed with ImmunoPulse IL-12 plus pembrolizumab is the first demonstrating efficacy in a predicted PD-1 non-responder population and shows that the combination represents a potentially important addition to the treatment landscape for metastatic melanoma patients who have progressed or are progressing on anti-PD-1 therapy,” said CEO Dan O’Connor.

OncoSec Financial Results

Separately, OncoSec Medical Inc. (NASDAQ:ONCS) reported fourth-quarter financial results that indicated a significant improvement in operational efficiencies. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million or (-$0.28) a share. The performance was an improvement from a net loss of (-$6.6) million reported last year.

OncoSec Medical Inc. (NASDAQ:ONCS) full-year net loss came in at (-$21.4) million or (-$1.06) a share, compared to a net loss of (-$26.9) million reported last year. The company attributes the decrease in net loss to a $2.2 million reduction in non-stock-based compensation. Research and development expenses also dropped from $14.7 million as of last year to $$12 million.

OncoSec Medical Inc. (NASDAQ:ONCS) exited the FY2017 with a total of $11.4 million in cash and cash equivalent compared to $28.7 million as of July 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Drop after Court Win

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Curiously, Orexigen Therapeutics, Inc. (NASDAQ:OREX) traded lower after a United States District Court issued a favorable ruling in a patent litigation case involving three patents for its obesity drug Contrave. Shares of the company fell 3.43% in Friday’s trading session to end the week at $1.97 a share.

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen Sell-Off

Friday’s sell-off strengthened a bearish tone that has seen the stock drop from $5.20 a share in February to current trading levels. While the stock is down by more than 60%, it is still above January’s trading levels.

Investor confidence has taken a hit following the termination of a collaboration agreement with Takeda. The agreement was for the commercialization of Orexigen’s obesity drug Contrave. The termination initially resulted in an increase in sales leading to net revenue increase, per unit, of 37%.

However, the increase was later offset by costs for commercialization of the drug. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has sought to change the situation by taking several steps to drive Contrave sales, in a bid to offset the costs. The company has already initiated speaker programs, as well as patient starter kits and promotional materials.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) faces an uphill task to boost its prospects in the already crowded obesity market. A variety of options exist from the likes of Vivus Inc., Novo Nordis,k and Arena Pharmaceuticals..

Contrave Patent Protection

The company is to provide a business update at the 2017 BIO investor forum on October 17, 2017. The Chief Executive Officer has already pointed out that the company is on a path to profitability by 2019. The executive made the remarks after the District Court extended the exclusivity of the company’s lead obesity drug through 2030.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has successfully defended its lead product, Contrave from Actavis which was planning to launch a generic version prior to the expiration of U.S Patents.

“Orexigen’s intent was to vigorously defend our intellectual property and we are very pleased with the Court’s decision upholding the validity of all of the patents involved in the case,” said Michael Narachi, President, and CEO of Orexigen. “The Court’s positive decision allows Orexigen to continue to fulfill its mission to provide innovative medicine to treat patients who are overweight or struggling with obesity.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OREX Symbol and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Why Volumes Exploded for DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) are up over 80% after the biopharmaceutical company announced that the U.S. Patent and Trade Office (USPTO) issued a patent covering covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083). DMPI stock is trading around the $2.00 level after closing at $1.12 yesterday. DelMar Shares gapped up to open at $1,80 before hitting their inter-day high of $2.29. Volumes have been strong. DMPI shares have a 30-day, daily traded volume of under 150,000 but by noon today over 16.8 million shares have traded.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)
Two day DMPI stock price chart

Delmar Pharmceuticals Patents

The newly issued patent strengthens DelMar Pharmaceuticals Inc (NASDAQ:DMPI) their intellectual property portfolio surrounding their VAL-083 manufacturing process. VAL-083 is billed by DelMar as a first-in-class DNA targeting agent that has successfully demonstrated clinical activity against a range of tumor-types in prior clinical trials sponsored by the U. S. National Cancer Institute (NCI). VAL-083 is currently protected by eight U.S. patents and eight patents outside of the U.S.

DMPI Stock

Ironically, DelMar Pharmaceuticals Inc (NASDAQ:DMPI) was downgraded by Maxim Group just one month ago – from a “Buy” to a “Hold”. DMPI stock had just made a new 52-week low of $1.05 last week. However the news surrounding the patent issuance now places the stock almost 100% off their lows. Unfortunately, long-term holders of DelMar Pharmaceutical stock are still well off their 52-week high of $6.90.

The micro-cap biopharmaceutical firm has only produced a profit for shareholders once in the past five years – in 2014. Per share losses in the other years range from (-$0.46) in 2015 to (-$1.12) in 2013. On top of that, dilution is an ongoing concern for long-term holders of the stock. In 2012 there were 3.31 million shares outstanding. By 2016 that number was reported at 10.95 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DMPI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Is RightsCorp Inc (OTCMKTS:RIHT) on the Rocket Pad?

RightsCorp Inc (OTCMKTS:RIHT)

RightsCorp Inc (OTCMKTS:RIHT) has been posting news that observers believe may propel shares higher in the coming weeks. Currently, RIHT shares are trading well above their 52-week low of $0.01 per share and are within striking distance of their $0.059 52-week high.

RightsCorp Inc (OTCMKTS:RIHT)
Daily Candle Bar for $RIHT

Intellectual property (IP) protection is a huge business. The U.S. Chamber of Commerce Intellectual Property Center has calculated the worth of intellectual property in the United States as being between $5 trillion and $5.5 trillion. Reports suggest that the U.S. economy loses $58 billion each year to copyright infringement including $16 billion in lost revenue to the owners of the IP, and $3 billion in lost tax revenue.

RightsCorp Inc (OTCMKTS:RIHT) provides data and analytics services to owners of copyrighted property such as artists or media firms. The company’s patent-pending digital technology focuses on the infringement of intellectual property rights and ensures that the legal owner’s rights are protected.

RightsCorp Recent History

At the end of February, RightsCorp Inc (OTCMKTS:RIHT) announced Mr. Cecil Bond Kyte as the company’s new Chief Executive Officer. Mr. Christopher Sabec, the Company’s current CEO, will serve as President and continue to spearhead RightsCorp’s intellectual property litigation support and copyright monetization services.

In late June, RightsCorp Inc (OTCMKTS:RIHT) announced that it has been granted an Israeli Patent for the company’s “System to Identify Multiple Copyright Infringements and Collecting Royalties”. Cecil Bond Kyte, CEO of Rightscorp, stated “Online piracy continues to be a major concern worldwide with Israel holding one of the highest rates outside Europe. Last year, it was recorded that approximately 66% watch movies and TV shows online with only 2% using legal direct-view websites. There is a need in Israel for content protection and our technology is an ideal solution for curbing piracy,”.

RightsCorp Can Scale

Clearly, there is positive movement in the ability for RightsCorp to execute on their business model. Their approach is to use their proprietary software to monitor global Peer‐to‐Peer (P2P) file sharing networks. As they monitor the P2P network, the software continuously scans for illegally downloaded digital media.

Once the software finds an illegally downloaded file, it sends an email to the internet service provider (ISP) using the notice format as specified in the Digital Millennium Copyright Act. The notice includes the date, time, song title and other specific technology identifiers to confirm the infringement by the ISP’s customer. Under Federal Copyright Law, once the ISP has actual knowledge of copyright infringements that take place using its network, it has specific duties in relation to the enforcement of the rights of the owners of the material in question. The ISP can legally cut off service to repeat offenders.

Fines for downloading IP without proper authority or permission can reach $150,000 per violation. However, RightsCorp provides these illegal users with a link to remit payment to Rightscorp who will then pay the IP owner a percentage of the collected fee. RightsCorp Inc (OTCMKTS:RIHT) believes this arrangement is economical and mutually beneficial to both the infringer and owner of the IP.

One thing is certain if the company is able to fully execute its business model – it could be a massive cash-flow generating machine.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RIHT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant

Superconductor Technologies Inc. (Nasdaq:SCON) Experiencing Massive Volumes

Superconductor Technologies Inc. (Nasdaq:SCON)

Shares of Austin, TX-based Superconductor Technologies Inc. (Nasdaq:SCON) are up over 30% on over 65 times normal average daily volumes. In November, Superconductor Technologies Inc. (Nasdaq:SCON) shares skyrocketed when the company was awarded $4.5 million for its Next Generation Electric Machines program by the U.S. Department of Energy’s Office of Energy Efficiency and Renewable Energy. Superconductor Technologies Inc. (Nasdaq:SCON) is developing and producing High Temperature Superconductor, or HTS, wire that bears the potential to revolutionize the electric power industry.

Yesterday, Superconductor Technologies Inc. (Nasdaq:SCON) was awarded a U.S. Patent enabled by STI’s superconducting wire manufacturing method. This patented process improves Conductus wire’s performance in the presence of a strong magnetic field. The properties of HTS allow wire to conduct electricity more efficiently from traditional copper wire through cooling power transmission to “critical” temperatures. Superconductor Tech markets its patented HTS technology under the brand name Conductus. HTS has the potential to revolutionize the Smart Grid market of generating and transmitting electricity in the United States.

Jeff Quiram, STI’s President and CEO stated in a press release “This new patent protects the foundation from which we will build high performance wire for our customers. The flexibility provided by our proprietary manufacturing process enables STI to build superconducting wire in very unique ways.”

Sales have declined YoY for Superconductor Technologies Inc. (Nasdaq:SCON). In 2011 and 2012 reported sales were $3.5 million. However, shareholders have seen steady improvement in earnings per share. In 2011, there was a loss of $75.69, followed by narrower losses and in 2015 the loss was $6.55.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/16/2017
Ticker Symbol SCON
Last Price a/o 10:23 AM EST  $                      1.48
Average Volume                1,250,000
Market Cap (mlns)  $                      5.91
Sales (mlns) $0.10
Shares Outstanding (mlns) 5.14
Share Float (mlns) 4.37
Shortable Yes
Optionable No
Inside Ownership 3.10%
Short Float 14.41%
Short Interest Ratio 0.5
Quarterly Return -9.29%
YTD Return -6.50%
Year Return -61.67%

Momenta Pharmaceuticals (Nasdaq: MNTA) Jumps After Hours on Teva (NYSE: TEVA) Patent Loss

Momenta Pharmaceuticals, Inc. – Nasdaq: MNTA

A U.S. Court invalidated patents granted to Teva Pharmaceuticals (NYSE: TEVA) for their multiple sclerosis drug Copaxone. That news sent shares of Momenta Pharmaceuticals (Nasdaq: MNTA) up over 8% in after-hours trading. In 2015, Momenta and Sandoz received FDA approval for their generic version of Copaxone. Reports are that Copaxone annually generates $4 billion in revenue for TEVA and that this court ruling could create a $1.2 Billion market for the generic version.

Cambridge, MA-based Momenta develops complex pharmaceutical products. The company utilizes proprietary technology-based methods to develop generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discover and develop of therapeutics for autoimmune indications.

Reported sales and EPS have been increasing for MNTA since 2013 when Momenta reported $35.5 million and -$2.13 respectively. In 2015 MNTA experienced a loss of $1.32 EPS on sales of $89.7 million. Nine firms follow Momenta Pharmaceuticals. Six rate MNTA shares as a “Strong Buy”, two rate the shares as a “Hold”. And one rates MNTA as a “Sell”. The consensus price target for MNTA is $18.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

 

Digital Ally, Inc. (Nasdaq: DGLY) Wins Appellate Verdict – Shares Rocket

Digital Ally, Inc. – Nasdaq: DGLY

Traders continue to push Kansas-based Digital Ally Inc. shares higher, on large volumes, after a favorable appeals court ruling found against Utility Associates, Inc. The shares, traded on the Nasdaq under ticker DGLY, began the week at $4.15 and reached $5.20 in after-hours trading on Thursday. 

Digital Ally™, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial fleet applications – focusing in Digital Video Imaging and Storage. Digital Ally has secured contracts and orders from law enforcement agencies, the U.S. Military and commercial fleets in all 50 states and more than 90 foreign countries.  

Stanton E. Ross, Chief Executive Officer of Digital Ally responded to news of the appeal court’s decision “This Judgment by the Federal Circuit is a huge legal victory for Digital and affirms what we have known all along — Utility has been threatening Digital and our customers with an invalid patent.” 

Two firms follow Digital Ally, Inc. and both rate DGLY shares as a “Strong Buy” with a consensus price target of $12. DGLY shares have never had positive EPS – 2011 (-$1.96), 2012 (-0.97), 2013 (-$1.17), 2014 (-$3.54), and in 2015 (-$2.77). Digital Ally reported sales in 2015 were $20 million – little changed from previous years. 

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/19/2017
Ticker Symbol DGLY
Last Price a/o 4:44 PM EST  $                      5.20
Average Volume 57,600
Market Cap $25.33 million
Sales $18.2 million
Shares Outstanding 5.39 million
Share Float 4.67 million
Shortable Yes
Optionable No
Inside Ownership 1.70%
Short Float 13.43%
Short Interest Ratio 10.89
Quarterly Return -17.54%
YTD Return 11.90%
Year Return -25.04%

Forward Pharma (Nasdaq: FWP) Receives $1.25 Billion Lawsuit Settlement From Biogen

Forward Pharma – Nasdaq: FWP

Forward Pharma shares rocketed up over 60% from their Friday close of $18.35 on news of a patent-infringement lawsuit settlement with Biogen (BIIB). The Danish company trades on the Nasdaq as an American Depository Share (ADR). According to reports, Biogen will pay Forward Pharma $1.25 Billion to settle the ongoing lawsuit over their multiple sclerosis drug Tecfidera.

Forward Pharma is a Danish biotechnology company focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as a pharmaceutical drug product to treat immune disorders such as multiple sclerosis and psoriasis. Major partners listed on Forward Pharma’s website include venture capital firms such as Nordic Biotech, Rosetta Capital, and BVF Partners.

Two firms follow Forward Biopharma and each rate FP shares as a “Strong Buy” despite no reported sales and negative EPS since 2012. Their consensus price target for FWP is $42.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

1/17/2017
Ticker Symbol FWP
Last Price a/o 11:29 AM EST $27.99
Average Volume 9,500
Market Cap $853 million
Sales
Shares Outstanding 46.5 million
Share Float 10.5 million
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.83%
Short Interest Ratio 9.14
Quarterly Return -11.57%
YTD Return 22.33%
Year Return 18.46%